ARTICLE | Clinical News
Gantenerumab: Phase III data
August 24, 2015 7:00 AM UTC
A biomarker analysis of 183 prodromal AD patients in the discontinued, double-blind, international Phase III SCarlet RoAD trial showed that once-monthly 105 and 225 mg subcutaneous gantenerumab every ...